The most comprehensive pharmaceutical-medical museum collection in Slovenia came to life in digital form
- The Lavička Collection, the most comprehensive pharmaceutical-medical collection in Slovenia is, due to the quality of its exhibits, one of the richest in Europe.
- Nearly one thousand exhibits in the Lavička Collection are now on view in digital form.
- By digitization of the Lavička Collection, Lek, a Sandoz company, has significantly broadened the access to knowledge.
Lek, a Sandoz company, has officially opened the digitized Lavička Collection, the most comprehensive pharmaceutical-medical museum in Slovenia. With the digitization of this collection they have significantly broadened access to this rich and unique source of knowledge, as all information about books, medical and pharmaceutical accessories, artefacts and other exhibits from the museum are now also available in verbal, pictorial and video form online and are accessible to everyone.
»The Government of the Republic of Slovenia proclaimed the Lavička Collection a cultural monument of national importance. This confirms the exceptional nature of the work done by Bohuslav Lavička, who succeeded in creating a collection which, due to the quality of its exhibits, is one of the richest in Europe. Lek, a Sandoz company, is a proud owner of this unique collection which has been on display in our premises for almost 30 years. During this time, more than 20,000 visitors have viewed the collection. By digitization, we have established a more up to date approach to bringing this collection closer to everyone interested in the development of knowledge through time« said Vojmir Urlep, President of the Board of Management of Lek, a Sandoz company.
»Digitization offers new possibilities of awareness about the importance of the collection and opens new ways of raising awareness of treasures that we possess, especially among the younger generations, those who do not know the world without the internet at all, or look into the world and learn about it only through »technological sensors«. Furthermore, an online access to the Lavička Collection will also provide global visibility« stressed Zoran Krstulović, Deputy Director at National University Library.
Through the museum with expert guidance
The Lavička Collection is divided into two parts, books and pharmaceutical-medical accessories. It contains more than 400 books and 500 items, created since early civilization to the 20th century. For the purpose of digitization, all exhibits were photographed from different sides and each individual item is presented in digital form. Visitors can browse between items and by clicking on an item view them in detail.
An important contribution of the digitized Lavička Collection is guidance through the museum with expert explanations. In this way, visitors to the digital museum are not left on their own. In-depth video explanations of a long-term curator and connoisseur of the Lavička Collection, Davor Poljanšek, guides them through the museum and the viewing of individual exhibits.
»Online presentation of the Lavička Collection represents an important step forward towards full digitization. At the same time it is the first step towards the establishment of a participatory museum which is not intended merely for viewing the exhibits, but for active participation of visitors,« highligted Vuk Ćosić, a digital strategist and project planner.
About the Lavička Collection
Bohuslav Lavička (1879-1942), a pharmacist of Czech descent, who worked from 1909 until his death in Tržič, enriched the Slovenian cultural space with his exceptional apothecary collection. Through the contacts he had for several decades with all major European antique dealers, an almost complete collection of pharmaceutical and medical accessories, artefacts and books was created.
After his death, the Germans wanted to move Bohuslav Lavička’s pharmaceutical-medical collection to Germany, however it was rescued by Professor Žontar from Kranj Museum, who together with his associates made sure that the collection was safely returned to the descendants of Bohuslav Lavička after the war. In 1978, the Lavička Collection was bought off by Lek, a Sandoz company, that first displayed it in 1986 in a museum in its business center in Ljubljana, where it is still housed today.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32